Melbourne-based civic compliance firm SARB Management Group wants to put the brakes on a case brought by tech company Vehicle Monitoring Systems over a patented method for detecting vehicles, in a dispute it says was finalised in a settlement reached almost five years ago.
IP Australia has rejected an application by Huawei Technologies to register the trade mark Nova after a challenge by radio giant Nova Entertainment, with a delegate finding the Chinese telecommunications company had failed to prove its intention to use the mark.
US biotechnology company ICOS has settled a dispute with Australian-based Arrow Pharma over the patents for erectile dysfunction drug Cialis, less than 12 months after a court upheld the validity of the patents in a separate case.
A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.
A Chicago jury has ordered an Australian maker of ugg boots to pay US-based footwear company Deckers Outdoor US$450,000 ($643,000) in damages for infringing the company’s trade mark.
Bauer Consumer Media has won a five-year legal battle over Evergreen Television’s Discover Downunder trade mark, with the Full Federal Court setting aside a prior IP Australia decision and deregistering the mark.
A group of 39 of Australia’s largest universities has managed to avoid paying its full $32.5 million annual fee to Copyright Agency Ltd, while a dispute over the terms of a licence remains unresolved.
Israeli drug maker Teva has won its bid for communications between Germany-based Boehringer and capsule manufacturers to help prove its claim that a patent at the centre of a dispute over the top-selling inhaler Spiriva was invalid for obviousness.
Treasury Wine Estates has won a nearly $352,000 judgment against an Australian company for allegedly violating its trade marks by making and selling copycat Penfolds products in China and Australia.
Drug maker Janssen will drop its long-running patent lawsuit against Alphapharm after the generic drug maker agreed to refrain from making products that allegedly infringe Janssen’s patents for its HIV drug Prezista.